AngioDynamics Inc. (ANGO) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended February 28, 2025 (Q3 Fiscal 2025) and the nine months ended February 28, 2025. AngioDynamics is a medical technology company focused on vascular access, peripheral vascular disease treatment, and oncology. The company is currently executing a strategic restructuring plan to shift from in-house manufacturing to an outsourced model, with a modified plan to maintain a limited presence in Queensbury, NY.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Sales | $72.0 million | $75.2 million | $212.3 million | $232.9 million |
| Gross Profit | $38.9 million | $35.9 million | $115.5 million | $116.2 million |
| Gross Margin | 54.0% | 47.7% | 54.4% | 49.9% |
| Net Loss | $(4.4) million | $(187.7) million | $(27.9) million | $(170.9) million |
| Diluted Loss Per Share | $(0.11) | $(4.67) | $(0.68) | $(4.26) |
| Cash and Equivalents | $44.8 million | (Balance Sheet: Feb 28, 2025) | ||
| Operating Cash Flow | $(28.9) million used (YTD 2025) | |||
| Debt | No outstanding long-term debt |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 4.2% in Q3 and 8.8% YTD compared to the prior year. This is primarily due to the divestiture of the PICC, Midline, dialysis, and BioSentry businesses, as well as the discontinuation of the RadioFrequency Ablation and Syntrax product lines.
- Segment Performance:
- Med Tech: Revenue grew 21.3% in Q3, driven by increased sales of the Auryon platform, thrombus management products (AngioVac/AlphaVac), and NanoKnife.
- Med Device: Revenue declined 17.6% in Q3, largely due to the aforementioned divestitures.
- Margin Expansion: Gross margin improved significantly to 54.0% in Q3 (up 630 bps) and 54.4% YTD (up 450 bps), driven by product mix shifts and cost management.
- Profitability Improvement: The net loss narrowed substantially to $4.4 million in Q3 from $187.7 million in the prior year. The prior year loss included a non-cash goodwill impairment charge of $159.5 million and a $19.3 million legal settlement expense related to litigation with C.R. Bard/BD.
- Restructuring Costs: The company recorded $3.1 million in restructuring charges in Q3 and $11.8 million YTD related to the manufacturing footprint restructuring plan.
Outlook, Risks, and Unusual Items
- Restructuring Plan: The company is transitioning to an outsourced manufacturing model. A modified plan announced in Q2 2025 will maintain a presence in Queensbury, NY for select operations. The plan is expected to generate $15.0 million in annual cost savings starting in fiscal year 2027.
- Legal Settlement: A settlement with BD regarding patent litigation was finalized in March 2024. The company paid a $7.0 million lump sum (with $3.5 million remaining payable as of Feb 28, 2025) and agreed to minimum annual payments of $2.5 million starting in fiscal 2025.
- Divestiture Earn-Out: The company achieved a sales milestone related to the divested PICC/Midline business in Q3 2025, recording a $5.5 million receivable expected to be paid in Q4 2025.
- Liquidity: Cash and cash equivalents were $44.8 million as of February 28, 2025. Management believes this is sufficient to meet capital needs for at least the next 12 months. A $15.0 million share repurchase program was authorized in July 2024; $1.7 million was utilized in the first two quarters of 2025, with $13.3 million remaining.
- Risks: Key risks include the execution of the manufacturing transition, ongoing product liability claims (approx. 120 claims regarding port products), and foreign currency fluctuations impacting international sales.
Investor Verification Checklist
- Verify the timeline and cost savings realization of the modified manufacturing restructuring plan.
- Monitor the status of the ~120 product liability claims regarding port products and potential accruals.
- Track the collection of the $5.5 million earn-out receivable from the Spectrum divestiture.
- Assess the impact of the BD settlement on future royalty payments and litigation exposure.
- Review the sustainability of gross margin improvements as the company transitions to third-party manufacturing.